Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Rhea-AI Summary

Exelixis (Nasdaq: EXEL) has announced its participation in three major investor conferences this March. The company will engage in fireside chat presentations at:

• TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 9:50 a.m. ET
• Barclays 27th Annual Global Healthcare Conference in Miami on March 11 at 1:30 p.m. ET
• 2025 Leerink Partners Global Healthcare Conference in Miami on March 12 at 10:40 a.m. ET

All presentations will be accessible via webcast through the company's website at www.exelixis.com under the Investors & News section's Event Calendar page. Replay recordings will remain available for a minimum of 30 days after the events.

-- Presentations to be webcast on www.exelixis.com --

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March:

• TD Cowen 45^th Annual Health Care Conference: Exelixis is scheduled to present at 9:50 a.m. ET / 6:50 a.m. PT on Tuesday, March 4 in Boston.
• Barclays 27^th Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:30 p.m. ET / 10:30 a.m. PT on Tuesday, March 11 in Miami.
• 2025 Leerink Partners Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Wednesday, March 12 in Miami.

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX^® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225401936/en/

Investors Contact:

Varant Shirvanian

Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

When is Exelixis (EXEL) presenting at the TD Cowen Healthcare Conference in March 2024?

Exelixis is presenting at the TD Cowen Conference on March 4 at 9:50 a.m. ET in Boston.

How can investors access Exelixis (EXEL) March 2024 conference presentations?

Investors can access the webcasts through www.exelixis.com under the Investors & News section's Event Calendar page.

Which investor conferences is Exelixis (EXEL) attending in Miami this March?

Exelixis is attending two Miami conferences: Barclays Global Healthcare Conference on March 11 and Leerink Partners Global Healthcare Conference on March 12.

How long will Exelixis (EXEL) March 2024 conference webcasts be available for replay?

The conference webcasts will be available for replay for at least 30 days after the events.